Citations

Citations to this article as recorded by  

• Clinical Insights on “Tolerability and Effectiveness of Glucagon‑Like Peptide‑1 Receptor Agonists in Patients with Inflammatory Bowel Disease”
  XiRui Yang, FengJie Xie
  Digestive Diseases and Sciences.2026; 71(2): 743.     CrossRef
• A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn’s Disease Activity Index: psychometric evaluation in adults with Crohn’s disease
  James D. Lewis, Aisha Vadhariya, Sylvia Su, Xian Zhou, Frederick Durand, Ariane K. Kawata, Larissa Stassek, Claudine Clucas, Stefan Schreiber
  Journal of Patient-Reported Outcomes.2025;[Epub]     CrossRef
• Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with Ulcerative Colitis and Crohn’s disease
  Ankit V. Jain, Sandeep Gopal, Anurag J. Shetty, Suresh Shenoy, B. V. Tantry, B. Unnikrishnan, Ramesh Holla, Rishit Anand
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Clinical outcome assessment may be a more useful tool for supporting inflammatory bowel disease clinical practice than just patient-reported outcome measures
  Nagesh Kamat, Gaurav Patil, Ankit Dalal, Amit Maydeo
  Current Medical Research and Opinion.2025; 41(6): 1041.     CrossRef
• Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review
  Xavier Calvet, Maria Giovanna Ferrario, Vanessa Marfil, Santos Armenteros, Manuel Barreiro-de Acosta
  Journal of Crohn’s and Colitis.2025;[Epub]     CrossRef
• AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study
  Raluca Lupusoru, Lavinia Cristina Moleriu, Ruxandra Mare, Ioan Sporea, Alina Popescu, Roxana Sirli, Adrian Goldis, Camelia Nica, Tudor Voicu Moga, Bogdan Miutescu, Iulia Ratiu, Oana Belei, Laura Olariu, Victor Dumitrascu, Radu Dumitru Dragomir
  International Journal of Molecular Sciences.2025; 27(1): 201.     CrossRef
• Depression and active disease are the major risk factors for fatigue and sleep disturbance in inflammatory bowel disease with consequent poor quality of life: Analysis of the interplay between psychosocial factors from the developing world
  Partha Pal, Rupa Banerjee, Polina Vijayalaxmi, D. Nageshwar Reddy, Manu Tandan
  Indian Journal of Gastroenterology.2024; 43(1): 226.     CrossRef
• Research Progress in the Study of Biomarkers for Diagnosing Ulcerative Colitis or Assessing Its Activity
  琳 杨
  Advances in Clinical Medicine.2024; 14(01): 1167.     CrossRef
• A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease
  Hyoun Woo Kang
  Intestinal Research.2024; 22(1): 3.     CrossRef
• The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross‐sectional study
  Dipesh H. Vasant, Gaurav B. Nigam, Sebastian Bate, Shaheen Hamdy, Jimmy K. Limdi
  Alimentary Pharmacology & Therapeutics.2023; 58(1): 26.     CrossRef
• Current and emerging biomarkers for ulcerative colitis
  Jan K. Nowak, Rahul Kalla, Jack Satsangi
  Expert Review of Molecular Diagnostics.2023; 23(12): 1107.     CrossRef